



## Atreca Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

May 13, 2020

SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that a trial in progress poster will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program being held from May 29 to May 31, 2020. The poster will describe the design of the company's ongoing Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers.

### Details of Atreca's poster presentation:

Abstract Title: First-in-human Phase 1b study of ATRC-101, an engineered version of a patient-derived antibody targeting a tumor-restricted ribonucleoprotein complex.

Session Title: Developmental Therapeutics – Immunotherapy

The abstract can be found on the [ASCO website](#) and the poster will be made available on the company's website once the virtual program begins on Friday, May 29 at 8:00 a.m. EDT.

### About ATRC-101

ATRC-101 is a monoclonal antibody derived from an antibody identified using Atreca's discovery platform. ATRC-101 is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology. This mechanism involves systemic delivery of an antibody that has been shown in preclinical models to engage the innate immune system, cause remodeling of the tumor microenvironment and drive T cell-mediated destruction of tumor cells. Atreca has identified the target of ATRC-101 as a ribonucleoprotein (RNP) complex. Underlining the rationale for human testing, ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. Further, ATRC-101 has been shown to react in vitro with a majority of human ovarian, non-small cell lung, colorectal, breast cancers and acral melanoma samples from multiple patients.

### About Atreca, Inc.

Atreca is a biopharmaceutical company developing novel antibody-based cancer immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit [www.atreca.com](http://www.atreca.com).

### Forward-Looking Statements

This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "believe," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at [www.sec.gov](http://www.sec.gov), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

### Contacts

Atreca, Inc.  
Herb Cross  
Chief Financial Officer  
[info@atreca.com](mailto:info@atreca.com)

Investors:  
Alex Gray, 650-779-9251  
[agray@atreca.com](mailto:agray@atreca.com)

Media:  
Sheryl Seapy, 213-262-9390  
[sseapy@w2ogroup.com](mailto:sseapy@w2ogroup.com)  
Source: Atreca, Inc.



Source: Atreca, Inc.